Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024

In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the Dana-Farber Cancer Institute, joins host Amalya Sargsyan to discuss Botensilimab, a next-generation anti-CTLA-4 therapy for immunotherapy. Dr. Schlechter shares his involvement in trials, highlighting the drug’s innovation in overcoming resistance in immune therapies, particularly in MSS colorectal cancer.

Dr. Benjamin Schlechter is a Senior Physician at Dana-Farber Cancer Institute, specializing in gastrointestinal cancers, including colorectal, anal, pancreatic, and neuroendocrine cancers. Previously, he served as the Director of Inpatient Hematology and Oncology at Beth Israel Deaconess Medical Center and was the Assistant Program Director for the Internal Medicine Residency Program.

Dr. Amalya Sargsyan is a Medical Oncologist at Yeolyan Center,  a Research Physician at the Immune Oncology Research Institute, and Senior Editor at Oncodaily. She holds an MD from Yerevan State Medical University and an MSc in Precision Medicine from the University of Cyprus.

Dr. Sargsyan completed her clinical training at the Bank of Cyprus Oncology Center and has been honored with an ASCO IDEA award.  Her research focuses on the potential of novel immune checkpoint inhibitors (ICI) in low- and middle-income countries (LMICs), aiming to bridge disparities and enhance access to innovative cancer care.